Upcoming Webinars

Bone Club Series

Join SIO for an intermediate-level (200) musculoskeletal (MSK) three-part webinar series. Part one will focus on the interventional treatment of malignant and metastatic bone lesions in both the axial and appendicular skeleton, covering techniques like ablation, cementation, and embolization. Part two willl focus on the finer details of patient evaluation and procedural techniques for benign bone lesions, demonstrating bone grafting for UBC/ABC. Part three will addresses the general guidelines and physiology for the management of oncologic pain using cryoneurolysis, techniques for managing chest wall masses and ablative options for management of aggressive pelvic disease tumors.

To get the most out of the series, we recommend registering for all three sessions.

Part 1: How I Do It—From Imaging Workup to Intervention: Metastatic/Malignant Bone Lesions

Wednesday, 24 September 2025 | 7 – 8:30 p.m. ET

Faculty

Moderator

Gina Landinez, MD

Baptist Health South Florida, Miami Vascular Specialists

Faculty Panel

Jason Levy MD, FSIR

Northside Radiology Associates

Marwan Moussa, MD

Beth Israel Deaconess Medical Center

Brandon Key, MD

Froedtert & Medical College of Wisconsin

Register Now

Part 2: How I Do It—From Imaging Workup to Intervention: Benign MSK Lesions

Wednesday, 8 October 2025 | 7 – 8:30 p.m. ET

Faculty

Moderator

Sirish Kishore, MD

Stanford University

Faculty Panel

Junjian Huang, MD

Emory Healthcare

Shantanu Warhadpande MD

University of Michigan

John David Prologo, MD

Emory Healthcare

Register Now

Part 3: How I Do It—From Imaging Workup to Intervention: Cryoneurolysis for Pain

Wednesday, 11 November 2025 | 7 – 8:30 p.m. ET– 8:30 p.m. ET

Faculty

Moderator

Sirish Kishore, MD

Stanford University

Faculty Panel

Junjian Huang, MD

Emory Healthcare

Shantanu Warhadpande MD

University of Michigan

John David Prologo, MD

Emory Healthcare

Register Now

Bone Club is supported by:

HCC Webinar Series

Join SIO for a three-part webinar series on hepatocellular carcinoma (HCC) this fall. Part one will cover advances in treatment with a shift toward combination therapies and sequencing strategies to optimize patient outcomes. Part two will explore the role of immunotherapy in HCC, including combinations with locoregional therapies, mechanisms of resistance, biomarker predictions and other therapeutic targets. Part three will highlight ongoing critical trials of combination locoregional therapy and immunotherapy in the liver.

To get the most out of the series, we recommend registering for all three sessions.

Part 1: Advancing HCC Treatment: Sequencing Strategies and Managing Combination Therapies

Tuesday, 30 September 2025 | 7 – 8 p.m. ET

Faculty

Moderator

Julius Chapiro, MD, PhD

Yale University

Faculty Panel

Richard Finn, MD

University of California Los Angeles

Nicholas Fidelman, MD

University of California San Francisco

Register Now

Part 2: Integrating Immunotherapy with Locoregional Therapies in HCC: Mechanisms, Biomarkers, and Resistance

Wednesday, 22 October 2025 | 7 p.m. ET

Faculty

Moderator

Julius Chapiro, MD, PhD

Yale University

Faculty Panel

Terrance Gade, MD, PhD

University of Pennsylvania

Sarah Manes

Global Liver Institute

Anjana Pillai, MD

University of Chicago

Michael Soulen, MD

University of Pennsylvania

Register Now

Part 3: Ongoing Critical Trials of Combination Locoregional Therapy and Immunotherapy in the Liver

Tuesday, 4 November 2025 | 7 p.m. ET

Faculty

Moderator

Zach Berman, MD

UC San Diego

Faculty Panel

Adam Burgoyne, MD, PhD

UC San Diego

Kirema Garcia-Reyes, MD

Mount Sinai

Christopher Malone, MD

Washington University

Register Now

This webinar series is sponsored by:

Targeting Tumors from Within: Intratumoral Therapies and Team-Based Care in Metastatic Melanoma

Postponed: Stay tuned for more details

Join us for an engaging webinar titled “Targeting Tumors from Within: Intratumoral Therapies and Team-Based Care in Metastatic Melanoma,” sponsored by Replimune and Johnson & Johnson. This session will explore the evolving treatment landscape for advanced melanoma, with a particular focus on patients who have progressed on PD-1 inhibitors. Attendees will gain valuable insights into second-line treatment strategies, including the role of oncolytic immunotherapies.

Faculty

Rahul Sheth, MD, FSIR

MD Anderson Cancer Center

Michael Wong, MD, PhD, FRCPC

Roswell Park Comprehensive Cancer Center

This webinar is sponsored by:

Advancing Ablation: Clinical Perspectives on Emprint™ and OsteoCool™

Thursday, 25 September 2025 | 6 – 7 p.m. ET

This panel discussion will feature leading interventional radiologists sharing their clinical experience with microwave and radiofrequency ablation technologies — specifically Emprint™ Microwave Ablation and OsteoCool™ RF Ablation. The session will highlight treatment strategies, case insights, and procedural considerations across soft tissue and bone tumor applications.

Faculty

Moderator

Jack Jennings, MD, PhD, FSIR

Washington University School of Medicine

Faculty Panel

Jawad Hussain, MD, MS

Commonwealth Interventional Radiology

Nicole Keefe, MD

University of North Carolina

Rahul Sheth, MD, FSIR

MD Anderson Cancer Center

Register Now

This webinar is sponsored by

Advancing HCC Treatment: Sequencing Strategies and Managing Combination Therapies

Tuesday, 30 September 2025 | 7 – 8 p.m. ET

Join SIO for a three-part HCC webinar series this fall. This webinar will cover advances in treatment of hepatocellular carcinoma (HCC) with a shift towards combination therapies and sequencing strategies to optimize patient outcomes.

Faculty

Moderator

Julius Chapiro, MD, PhD

Yale University

Faculty

Richard Finn, MD

University of California Los Angeles

Nicholas Fidelman, MD

University of California San Francisco

Register Now

This webinar is sponsored by:

Integrating Immunotherapy with Locoregional Therapies in HCC: Mechanisms, Biomarkers, and Resistance

Wednesday, 22 October 2025 | 7 p.m. ET

Join SIO for a three-part HCC webinar series this fall. This webinar will cover the role of immunotherapy as a treatment for HCC and in combination with locoregional therapies, as well as looking at mechanisms of resistance, biomarker predictions and other therapeutic targets.

Faculty

Moderator

Julius Chapiro, MD, PhD

Yale University

Faculty

Terrance Gade, MD, PhD

University of Pennsylvania

Sarah Manes

Global Liver Institute

Anjana Pillai, MD

University of Chicago

Michael Soulen, MD

University of Pennsylvania

Register Now

This webinar is sponsored by:

Ongoing Critical Trials of Combination Locoregional Therapy and Immunotherapy in the Liver

Tuesday, 4 November 2025 | 7 p.m. ET

This webinar, funded by AstraZeneca, will cover ongoing critical trials of combination locoregional therapy and immunotherapy in the liver.

Faculty

Moderator

Zach Berman, MD

UC San Diego

Faculty

Adam Burgoyne, MD, PhD

UC San Diego

Kirema Garcia-Reyes, MD

Mount Sinai

Christopher Malone, MD

Washington University

Register Now

This webinar is sponsored by: